Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study

Fabiano Di Marco, Marco Guazzi, Marco Vicenzi, Pierachille Santus, Mario Cazzola, Maria Pappalettera, Paola Castellotti, Stefano Centanni

Research output: Contribution to journalArticle

Abstract

Background: Some studies suggest that the sympathetic nervous system and the renin-angiotensin system are activated in patients with chronic obstructive pulmonary disease (COPD), potentially resulting in negative cardiopulmonary and muscular effects. The aim of this pilot study was to evaluate the efficacy of an angiotensin converting enzyme (ACE) inhibitor on cardiopulmonary exercise performance in COPD patients. Primary outcome was the effect of treatment on the ventilatory response to exercise (VE/VCO2 slope). Secondary outcomes were exercise variables evaluated by the cardiopulmonary exercise test, and pulmonary function according to ACE genotyping. Methods: 4 weeks treatment with enalapril (10 mg od) or placebo was evaluated in 21 COPD patients (FEV1 <60%) and without cardiovascular disease in a double-blind, cross-over study. Results: 18 patients completed the study. Enalapril did not exert a significant effect on exercise VE/VCO2 slope or on peak O2 consumption. However enalapril significantly improved peak O2 pulse and work rate compared to placebo. A mild but significant worsening of the diffusion capacity of the lung was observed. ACE genotype did not significantly affect patients' response to treatment, except for a trend toward a more evident effect of treatment in patients with II ACE genotype in terms of O2 pulse and gas diffusion. Conclusions: In this pilot study, ACE inhibition did not affect the ventilatory response to exercise in COPD patients. However, treatment resulted in improvement in work rate and O2 pulse, suggesting that ACE inhibitor therapy warrants consideration and may provide beneficial effect on the cardiovascular response to exercise in COPD.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Pulmonary diseases
Enalapril
Chronic Obstructive Pulmonary Disease
Peptidyl-Dipeptidase A
Exercise
Angiotensin-Converting Enzyme Inhibitors
Enzyme inhibition
Diffusion in gases
Angiotensins
Heart Rate
Neurology
Genotype
Placebos
Renin
Enzyme Therapy
Lung Volume Measurements
Therapeutics
Sympathetic Nervous System
Renin-Angiotensin System
Exercise Test

Keywords

  • Angiotensin-converting enzyme inhibitors
  • Chronic obstructive pulmonary disease
  • Exercise capacity
  • Polymorphism

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease : A pilot study. / Di Marco, Fabiano; Guazzi, Marco; Vicenzi, Marco; Santus, Pierachille; Cazzola, Mario; Pappalettera, Maria; Castellotti, Paola; Centanni, Stefano.

In: Pulmonary Pharmacology and Therapeutics, Vol. 23, No. 3, 06.2010, p. 159-164.

Research output: Contribution to journalArticle

Di Marco, Fabiano ; Guazzi, Marco ; Vicenzi, Marco ; Santus, Pierachille ; Cazzola, Mario ; Pappalettera, Maria ; Castellotti, Paola ; Centanni, Stefano. / Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease : A pilot study. In: Pulmonary Pharmacology and Therapeutics. 2010 ; Vol. 23, No. 3. pp. 159-164.
@article{e042e2eae82341bb873c5b51e7281e3d,
title = "Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: A pilot study",
abstract = "Background: Some studies suggest that the sympathetic nervous system and the renin-angiotensin system are activated in patients with chronic obstructive pulmonary disease (COPD), potentially resulting in negative cardiopulmonary and muscular effects. The aim of this pilot study was to evaluate the efficacy of an angiotensin converting enzyme (ACE) inhibitor on cardiopulmonary exercise performance in COPD patients. Primary outcome was the effect of treatment on the ventilatory response to exercise (VE/VCO2 slope). Secondary outcomes were exercise variables evaluated by the cardiopulmonary exercise test, and pulmonary function according to ACE genotyping. Methods: 4 weeks treatment with enalapril (10 mg od) or placebo was evaluated in 21 COPD patients (FEV1 <60{\%}) and without cardiovascular disease in a double-blind, cross-over study. Results: 18 patients completed the study. Enalapril did not exert a significant effect on exercise VE/VCO2 slope or on peak O2 consumption. However enalapril significantly improved peak O2 pulse and work rate compared to placebo. A mild but significant worsening of the diffusion capacity of the lung was observed. ACE genotype did not significantly affect patients' response to treatment, except for a trend toward a more evident effect of treatment in patients with II ACE genotype in terms of O2 pulse and gas diffusion. Conclusions: In this pilot study, ACE inhibition did not affect the ventilatory response to exercise in COPD patients. However, treatment resulted in improvement in work rate and O2 pulse, suggesting that ACE inhibitor therapy warrants consideration and may provide beneficial effect on the cardiovascular response to exercise in COPD.",
keywords = "Angiotensin-converting enzyme inhibitors, Chronic obstructive pulmonary disease, Exercise capacity, Polymorphism",
author = "{Di Marco}, Fabiano and Marco Guazzi and Marco Vicenzi and Pierachille Santus and Mario Cazzola and Maria Pappalettera and Paola Castellotti and Stefano Centanni",
year = "2010",
month = "6",
doi = "10.1016/j.pupt.2010.01.004",
language = "English",
volume = "23",
pages = "159--164",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",
number = "3",

}

TY - JOUR

T1 - Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease

T2 - A pilot study

AU - Di Marco, Fabiano

AU - Guazzi, Marco

AU - Vicenzi, Marco

AU - Santus, Pierachille

AU - Cazzola, Mario

AU - Pappalettera, Maria

AU - Castellotti, Paola

AU - Centanni, Stefano

PY - 2010/6

Y1 - 2010/6

N2 - Background: Some studies suggest that the sympathetic nervous system and the renin-angiotensin system are activated in patients with chronic obstructive pulmonary disease (COPD), potentially resulting in negative cardiopulmonary and muscular effects. The aim of this pilot study was to evaluate the efficacy of an angiotensin converting enzyme (ACE) inhibitor on cardiopulmonary exercise performance in COPD patients. Primary outcome was the effect of treatment on the ventilatory response to exercise (VE/VCO2 slope). Secondary outcomes were exercise variables evaluated by the cardiopulmonary exercise test, and pulmonary function according to ACE genotyping. Methods: 4 weeks treatment with enalapril (10 mg od) or placebo was evaluated in 21 COPD patients (FEV1 <60%) and without cardiovascular disease in a double-blind, cross-over study. Results: 18 patients completed the study. Enalapril did not exert a significant effect on exercise VE/VCO2 slope or on peak O2 consumption. However enalapril significantly improved peak O2 pulse and work rate compared to placebo. A mild but significant worsening of the diffusion capacity of the lung was observed. ACE genotype did not significantly affect patients' response to treatment, except for a trend toward a more evident effect of treatment in patients with II ACE genotype in terms of O2 pulse and gas diffusion. Conclusions: In this pilot study, ACE inhibition did not affect the ventilatory response to exercise in COPD patients. However, treatment resulted in improvement in work rate and O2 pulse, suggesting that ACE inhibitor therapy warrants consideration and may provide beneficial effect on the cardiovascular response to exercise in COPD.

AB - Background: Some studies suggest that the sympathetic nervous system and the renin-angiotensin system are activated in patients with chronic obstructive pulmonary disease (COPD), potentially resulting in negative cardiopulmonary and muscular effects. The aim of this pilot study was to evaluate the efficacy of an angiotensin converting enzyme (ACE) inhibitor on cardiopulmonary exercise performance in COPD patients. Primary outcome was the effect of treatment on the ventilatory response to exercise (VE/VCO2 slope). Secondary outcomes were exercise variables evaluated by the cardiopulmonary exercise test, and pulmonary function according to ACE genotyping. Methods: 4 weeks treatment with enalapril (10 mg od) or placebo was evaluated in 21 COPD patients (FEV1 <60%) and without cardiovascular disease in a double-blind, cross-over study. Results: 18 patients completed the study. Enalapril did not exert a significant effect on exercise VE/VCO2 slope or on peak O2 consumption. However enalapril significantly improved peak O2 pulse and work rate compared to placebo. A mild but significant worsening of the diffusion capacity of the lung was observed. ACE genotype did not significantly affect patients' response to treatment, except for a trend toward a more evident effect of treatment in patients with II ACE genotype in terms of O2 pulse and gas diffusion. Conclusions: In this pilot study, ACE inhibition did not affect the ventilatory response to exercise in COPD patients. However, treatment resulted in improvement in work rate and O2 pulse, suggesting that ACE inhibitor therapy warrants consideration and may provide beneficial effect on the cardiovascular response to exercise in COPD.

KW - Angiotensin-converting enzyme inhibitors

KW - Chronic obstructive pulmonary disease

KW - Exercise capacity

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=77950340718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950340718&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2010.01.004

DO - 10.1016/j.pupt.2010.01.004

M3 - Article

C2 - 20096799

AN - SCOPUS:77950340718

VL - 23

SP - 159

EP - 164

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 3

ER -